Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 11/2007

01-11-2007 | Original Article

Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice

Authors: Roberta Castriconi, Alessandra Dondero, Michele Cilli, Emanuela Ognio, Annalisa Pezzolo, Barbara De Giovanni, Claudio Gambini, Vito Pistoia, Lorenzo Moretta, Alessandro Moretta, Maria Valeria Corrias

Published in: Cancer Immunology, Immunotherapy | Issue 11/2007

Login to get access

Abstract

Aim

Several lines of evidence suggest that NK cell immunotherapy may represent a successful approach in neuroblastoma (NB) patients refractory to conventional therapy. However, homing properties, safety and therapeutic efficacy of NK cell infusions need to be evaluated in a suitable preclinical murine NB model.

Materials and methods

Here, the therapeutic efficacy of NK cell infusions in the presence or absence of NK-activating cytokines have been evaluated in a NB metastatic model set up in NOD/scid mice, that display reduced functional activity of endogenous NK cells.

Results

In NOD/scid mice the injected NB cells rapidly reached all the typical sites of metastatization, including bone marrow. Infusion of polyclonal IL2-activated NK cells was followed by dissemination of these cells into various tissues including those colonized by metastatic NB cells. The early repeated injection of IL2-activated NK cells in NB-bearing NOD/scid mice significantly increased the mean survival time, which was associated with a reduced bone marrow infiltration. The therapeutic effect was further enhanced by low doses of human recombinant IL2 or IL15.

Conclusion

Our results indicate that NK-based adoptive immunotherapy can represent a valuable adjuvant in the treatment of properly selected NB patients presenting with metastatic disease, if performed in a minimal residual disease setting.
Literature
1.
Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203–216PubMedCrossRef
2.
Schwab M, Westermann F, Hero B, Berthold F (2003) Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4:472–480PubMedCrossRef
3.
Brodeur GM, Maris JM (2001). Neuroblastoma. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincott–Raven, Philadelphia, pp 895–937
4.
Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477PubMed
5.
Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. J Clin Oncol 17:2264–2279PubMed
6.
Brenner MK, Heslop H, Krance R et al (2000) Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther 11:1477–1488PubMedCrossRef
7.
Rousseau RF, Haight AE, Hirschmann-Jax C et al (2003) Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101:1718–1726PubMedCrossRef
8.
Handgretinger R, Baader P, Dopfer R et al (1992) A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35:199–204PubMedCrossRef
9.
Kushner BH, Kramer K, Cheung NK (2001) Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19:4189–4194PubMed
10.
Ozkaynak MF, Sondel PM, Krailo MD et al (2000) Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after stem cell tranplantation: a children’s cancer group study. J Clin Oncol 18:4077–4085PubMed
11.
Kuppen PJ, Gorter A, Hagenaars M et al (2001) Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model. Immunol Rev 184:236–243PubMedCrossRef
12.
Basse PH, Whiteside TL, Chambers W, Herberman RB (2001) Therapeutic activity of NK cells against tumors. Int Rev Immunol 20:439–501PubMed
13.
Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA (1994) A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 91:9626–9630PubMedCrossRef
14.
Koehl U, Sorensen J, Esser R et al (2004) IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 33:261–266PubMedCrossRef
15.
Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–7305PubMedCrossRef
16.
Passweg JR, Sern M, Koehl U, Uharek L, Tichelli A (2005) Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant 35:637–643PubMedCrossRef
17.
18.
Castriconi R, Dondero A, Augugliaro R et al (2004) Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 101:12640–12645PubMedCrossRef
19.
Castriconi R, Dondero A, Corrias MV et al (2004) Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of dnam-1/pvr interaction. Cancer Res 64:9180–9184PubMedCrossRef
20.
Airoldi I, Lualdi S, Bruno S et al (2003) Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. Br J Cancer 88:1527–1536PubMedCrossRef
21.
Iyoda T, Shimoyama S, Liu K et al (2002) The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 195:1289–1302PubMedCrossRef
22.
Shultz LD, Schweitzer PA, Christianson SW et al (1995) Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154:180–191PubMed
23.
Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M (2003) Doxorubicin-loaded Fab’ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 63:86–92PubMed
24.
Croce M, Meazza R, Orengo AM et al (2005) Sequential immuno-gene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin Cancer Res 11:735–742PubMed
25.
London L, Perussia B, Trinchieri G (1986) Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. J Immunol 137:3845–3854PubMed
26.
Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA (1997) A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99:937–943PubMedCrossRef
27.
Dunne J, Lynch S, O’Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG (2001) Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 167:3129–3138PubMed
28.
Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA (2002) In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100:3633–3638PubMedCrossRef
29.
Loza MJ, Perussia B (2004) Differential regulation of NK cell proliferation by type I and II IFN. Int Immunol 16:23–32PubMedCrossRef
30.
Lozupone F, Pende D, Bugio VL et al (2004) Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res 64:378–385PubMedCrossRef
31.
Hagenaars M, Zwaveling S, Kuppen PJ et al (1998) Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses. Int J Cancer 78:783–789PubMedCrossRef
32.
Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH (1991) Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174:479–488PubMedCrossRef
33.
De Bernardi B, Pianca C, Pistamiglio P et al (2001) Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 19:183–190PubMed
34.
Matthay KK, Villablanca JG, Seeger RC et al (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s cancer group. N Engl J Med 341:1165–1173PubMedCrossRef
35.
Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK (2000) Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a children’s cancer group study. J Clin Oncol 18:4067–4076PubMed
36.
Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854PubMedCrossRef
37.
Corrias MV, Occhino M, Croce M et al (2001) Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens 57:110–117PubMedCrossRef
38.
Raffaghello L, Prigione I, Bocca P et al (2005) Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 24:4634–4644PubMedCrossRef
39.
Valteau-Couanet D, Leboulaire C, Maincent K et al (2002) Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 100:2554–2561PubMedCrossRef
40.
Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA (2004) NK cell and DC interactions. Trends Immunol 25:47–52PubMedCrossRef
41.
Moretta A (2002) Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2:957–964PubMedCrossRef
42.
43.
Montaldo PG, Carbone R, Corrias MV, Cornaglia-Ferraris P, Ponzoni M (1994) Synergic differentiation-promoting activity of interferon-γ and tumor necrosis factor: role of receptor regulation on human neuroblasts. J Natl Cancer Inst 86:1694–1701PubMedCrossRef
Metadata
Title
Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice
Authors
Roberta Castriconi
Alessandra Dondero
Michele Cilli
Emanuela Ognio
Annalisa Pezzolo
Barbara De Giovanni
Claudio Gambini
Vito Pistoia
Lorenzo Moretta
Alessandro Moretta
Maria Valeria Corrias
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-007-0317-0

Other articles of this Issue 11/2007

Cancer Immunology, Immunotherapy 11/2007 Go to the issue

Original Article

Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome

Original Article

Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients

Short Communication

Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

Original Article

TGF-β insensitive dendritic cells: an efficient vaccine for murine prostate cancer

Original Article

Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival

Original Article

NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits